-
Roth Affirms GenVec (GNVC) at 'Buy'; Novartis Partnership is Entering 'Prime Time'
-
GenVec (GNVC) to Place $9M of Common at $3.15/Share
-
Roth Capital Resumes GenVec (GNVC) at Buy; Novartis (NVS) Program Reinvigorates Excitement
-
Unusual 11 Mid-Day Movers 3/30: ENCO, LGL, VIFL, SCKT, AEN Higher; GNVC, FONR, ZSTN, CHRS Lower
-
Notable Analyst Rating Changes 03/30: MHGC, COBZ, PRXL Upgraded; GENZ, RTI, GNVC Downgraded
-
Morning Movers 3/30: LGL, WEDC, OPXA, FIGI, BNHNA Higher; GNVC, CHGS, ZSTN, HPJ, MPG, OXM Lower
-
Roth Capital Downgrades GenVec (GNVC) to Hold
-
GenVec (GNVC) to Sell 14M Common and Warrant in Private Placement; Expects $28M in Gross Proceeds
-
Morning Movers 01/07: BKRS, ZIGO, EEE, SOMX, ZIXI, ONT, CITP Higher; GME, TSRA, CBK, PRXI Lower
-
Roth Capital Initiates Coverage on Biotechnology and Drugs Stocks

